(CHSRI) UBS (CH) - MSCI - Ratings and Ratios

Exchange: SW • Country: Switzerland • Currency: CHF • Type: Etf • ISIN: CH0368190739

Swiss Stocks, Equity Funds, Investment Funds

Description: CHSRI UBS (CH) - MSCI

The UBS ETF (CH) - MSCI Switzerland IMI Socially Responsible (CHF) A-dis is an exchange-traded fund that tracks the Morningstar Switzerland TME NR CHF index, providing exposure to Swiss equities that meet certain socially responsible investing (SRI) criteria.

As a Switzerland Equity ETF, it is designed to capture the performance of the Swiss market, with a focus on companies that adhere to environmental, social, and governance (ESG) principles. The funds underlying index is likely constructed using a rules-based methodology that screens out companies involved in controversial activities or with poor ESG track records.

From a performance perspective, key metrics to monitor include the funds tracking error relative to its benchmark, as well as its returns relative to peers in the Switzerland Equity ETF category. Additional KPIs to consider include the funds expense ratio, trading liquidity, and the overall composition of its holdings, including sector and stock-level exposures.

Investors should also be aware of the funds investment universe and the specific SRI criteria used to construct the underlying index. This may include factors such as carbon footprint, labor practices, and board composition. By understanding these underlying drivers, investors can better assess the funds potential for long-term performance and alignment with their values.

Additional Sources for CHSRI ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

CHSRI ETF Overview

Market Cap in USD 344m
Category Switzerland Equity
IPO / Inception 2017-09-11

CHSRI ETF Ratings

Growth Rating 41.1
Fundamental -
Dividend Rating 44.7
Rel. Strength -8.97
Analysts -
Fair Price Momentum 17.33 CHF
Fair Price DCF -

CHSRI Dividends

Dividend Yield 12m 1.97%
Yield on Cost 5y 2.65%
Annual Growth 5y 8.77%
Payout Consistency 97.1%
Payout Ratio %

CHSRI Growth Ratios

Growth Correlation 3m 39.2%
Growth Correlation 12m 47.3%
Growth Correlation 5y 53.2%
CAGR 5y 6.30%
CAGR/Max DD 5y 0.23
Sharpe Ratio 12m 0.61
Alpha -6.76
Beta 0.558
Volatility 9.90%
Current Volume 7k
Average Volume 20d 8.3k
Stop Loss 17.9 (-3%)
What is the price of CHSRI shares?
As of July 16, 2025, the stock is trading at CHF 18.46 with a total of 6,952 shares traded.
Over the past week, the price has changed by -0.03%, over one month by -0.74%, over three months by +7.37% and over the past year by +2.68%.
Is UBS (CH) - MSCI a good stock to buy?
Partly, yes. Based on ValueRay´s Analyses, UBS (CH) - MSCI (SW:CHSRI) is currently (July 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 41.06 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CHSRI is around 17.33 CHF . This means that CHSRI is currently overvalued and has a potential downside of -6.12%.
Is CHSRI a buy, sell or hold?
UBS (CH) - MSCI has no consensus analysts rating.
What are the forecasts for CHSRI share price target?
According to our own proprietary Forecast Model, CHSRI UBS (CH) - MSCI will be worth about 19.4 in July 2026. The stock is currently trading at 18.46. This means that the stock has a potential upside of +5.04%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 19.4 5%